Following multidisciplinary consultation, the patient was treated with the bendamustine plus rituximab (BR) regimen. Second, for WM patients with renal AL amyloidosis, choosing BR regimen as the first-line treatment is reasonable. However, during the treatment process, it is essential to closely monitor and actively prevent the adverse effects of this regimen, particularly severe infections which may have fatal consequences.

1 month ago

Review • Journal

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)

Rituxan (rituximab) • bendamustine

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study. (PubMed, Blood Cancer J)

ZR-CHOP demonstrates encouraging activity and acceptable safety in molecularly selected high-risk DLBCL, particularly in the MCD-like subgroup. (ClinicalTrials.gov number, NCT05290337).

1 month ago

P2 data • Journal

TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule)

TP53 mutation

Rituxan (rituximab) • Brukinsa (zanubrutinib)

RG1716009: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2031 --> Jan 2028

1 month ago

Trial completion date

Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)

Economic Analysis of Alliance A041202 CLL Study (clinicaltrials.gov)

P=N/A, N=55, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026

1 month ago

Trial completion date • HEOR

Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) (clinicaltrials.gov)

P1/2, N=12, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)

GLORIFY: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (clinicaltrials.gov)

P2, N=40, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Mar 2027 --> Sep 2029 | Trial primary completion date: Mar 2026 --> Mar 2028

1 month ago

Trial completion date • Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

Rituxan (rituximab) • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • Columvi (glofitamab-gxbm)

Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy. (PubMed, Kidney Med)

After lymphoma-directed therapy alone (R-CHOP/R-DHAP induction, autologous hematopoietic stem cell transplantation consolidation, and extended rituximab maintenance), both conditions achieved sustained remission...Both MCL and MN remained in remission for >2 years. This case highlights MCL-associated MN as a PLA2R/THSD7A/NELL-1 triple-negative entity where antineoplastic therapy alone induces renal remission, demonstrating both the paraneoplastic mechanism and the feasibility of intensive lymphoma treatment, including transplantation without renal compromise.

1 month ago

Journal

CCND1 (Cyclin D1)

Rituxan (rituximab)

UCDCC#303: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=24, Recruiting, University of California, Davis | Trial primary completion date: Feb 2026 --> Oct 2026

1 month ago

Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)

Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Zynlonta (loncastuximab tesirine-lpyl) • Truxima (rituximab-abbs)

STRIVE II: Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)

P2, N=52, Not yet recruiting, University of Alabama at Birmingham

1 month ago

New P2 trial

Rituxan (rituximab)

Anti-CD20 and -PD-1 antibody effects on proliferation, apoptosis and cell cycle of endometrial cancer cells. (PubMed, Oncol Lett)

Furthermore, the combination of Rituximab and Pembrolizumab resulted in enhanced and more potent suppression of cancer cell growth than either monotherapy alone. In conclusion, the combination of anti-CD20 antibody and PD-1 antibody exerts synergistic antiproliferative effects on EC cells in vitro.

1 month ago

Journal • PD(L)-1 Biomarker • IO biomarker

MS4A1 (Membrane Spanning 4-Domains A1)

Keytruda (pembrolizumab) • Rituxan (rituximab)

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Nave Chronic Lymphocytic Leukemia (clinicaltrials.gov)

P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center

1 month ago

New P2 trial

CD20 (Membrane Spanning 4-Domains A1)

clonoSEQ®

Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)

P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026

1 month ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human

CD20 (Membrane Spanning 4-Domains A1)

CD20 positive

Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831